For more than 50 years, Laboratorios Rubio, a family-owned company, has
been recognized for the development, manufacture and marketing of medicines
with high therapeutical value for specialists as well as of certain drugs for
life-threatening diseases, with long expertise in niche markets.
Laboratorios Rubio's determination to meet the health needs of every single
patient has led the company to be distinguished as per being pioneer of
products targeted to low incidence diseases which affect only
to a small number of patients and that require the development of specific
pharmaceutical products to treat them.
Within the niche market strategy, Laboratorios Rubió has been pioneer and innovative company among the Spanish pharmaceutical companies focus on, but not limited, to therapeutical areas such as: CNS, Anti-rheumatic, Nephrology, Urology, CV, GI, Psychiatry, etc. It is worth highlighting the success of RUBIFEN® & RUBIFEN® RETARD (Methylphenidate), RESINCALCIO® (Calcium Polystyrene Sulphonate), RESINSODIO® (Sodium Polystyrene Sulphonate), RESINCOLESTIRAMINA® (Cholestyramine), RUBI-DIET® NEFRO & RUBI-DIET® NEFRO PLUS (nutrition in CKD) and MELATONIN.
For more information, please visit us on www.laboratoriosrubio.com
Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)
Primary business activity
Categories affiliated with LABORATORIOS RUBIO SA
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation